<DOC>
	<DOCNO>NCT00933777</DOCNO>
	<brief_summary>Dose find part : A phase I clinical trial evaluate safety combine sorafenib everolimus treatment patient relapse solid tumor ( finish ) . Extension part : Treatment non-small cell lung cancer ( NSCLC ) KRAS mutation ≥ 1st relapse ( recruit )</brief_summary>
	<brief_title>SORAVE - Sorafenib Everolimus Solid Tumors</brief_title>
	<detailed_description>Dose find part : Patients recruit receive combination define sorafenib dose ( 2x400mg ) increase dose everolimus ( 2.5mg , 5mg , 7.5mg , 10mg ) . There run-in phase 14 day everolimus follow combination sorafenib+everolimus start day 15 . The combination continue long tolerated patient patient benefit treatment accord RECIST criterion . The maximal tolerate dose establish 3+3 design . Patients recruit sequentially least 14 day apart . The next dose level accord 3+3 design initiate patient previous dose level reach day 29 . Extension part : Patients treat dose 7,5 mg Everolimus 14 day ( run-in phase ) sorafenib 2x 400 mg progression</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients solid tumor relapse and/or refractory standard therapy ( dose find part ) , KRAS mutate NSCLC patient ≥ 1st relapse extension phase ≥ 18 year age Performance status ECOG 02 Life expectancy least 12 week Subjects least one measurable ( CT MRI ) lesion Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ( ANC ) ≥ 1,500 /mm3 Platelet count ≥ 100 000/µL Total bilirubin ≤ 1,5x upper limit normal ( ULN ) ALT AST ≤ 2,5x ULN ( ≤ 5x ULN patient liver involvement ) Alkaline phosphatase &lt; 4x ULN Potassium within normal limit ( WNL ) correctable supplement Total calcium ( correct serum albumin ) WNL correctable supplement Magnesium WNL correctable supplement PTINR/PTT &lt; 1.5 x ULN [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist ] Serum creatinine ≤ 1.5 x upper limit normal creatinine clearance ( CrCl ) ≥ 50 ml/min calculate either CockcroftGault 24 hour urine collection More 14 day since previous systemic therapy , radiotherapy surgery Negative urine serum HCG woman childbearing potential Signed date informed consent start specific protocol procedure Squamous cell carcinoma histology nonsmall cell lung cancer History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active Coronary Arterial Disease ( CAD ) , ( MI 6 month prior study entry allow ) ; cardiac arrythmias require antiarrythmic therapy ( except , control beta blocker digoxin ) uncontrolled hypertension ; Extension phase : Long QTSyndrome Active skin , mucosa , ocular GI disorder grade &gt; 1 Uncontrolled diabetes ≥ grade 3 hypercholesterolemia/hypertriglyceridemia ≥ grade 2 hypercholesterolemia / hypertriglyceridemia history CAD ( despite lipid lower treatment give ) Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus sorafenib ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) History HIV infection previously seropositive virus History Hepatitis B or/and C previously seropositive Hepatitis B or/and C virus Leptomeningeal uncontrolled brain metastasis , include patient continue require glucocorticoid intrathecal chemotherapy brain leptomeningeal metastasis ( document lumbar puncture ) Treatment investigational drug within previous 14 day Patients seizure disorder require antiepileptic History organ allograft Patients evidence history bleed diathesis Patients undergoing renal dialysis Previous treatment mTOR inhibitor and/or know hypersensitivity mTOR inhibitor Past current history cancer entry diagnosis EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry Any person institution assignment respective authority Any medical , mental psychological condition opinion investigator would permit patient complete study understand patient information Women pregnant breast feeding , woman able conceive unwilling practice effective method birth control ( safe hormonal method or/and barrier contraception ) study 2 month last study drug intake For Extension part : Patients medication prolongs QTc withdrawn ( QTc prolong medication withdrawn must time interval least 7 day start treatment sorafenib , case amiodarone time interval least 90 day ) Testing Hepatitis B mandatory</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>